Oxford Biomedica plc (LON:OXB)
571.00
-13.00 (-2.23%)
Jul 24, 2026, 5:12 PM GMT
Oxford Biomedica Balance Sheet
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 96.88 | 60.65 | 103.72 | 141.29 | 108.94 |
Cash & Short-Term Investments | 96.88 | 60.65 | 103.72 | 141.29 | 108.94 |
Cash Growth | 59.74% | -41.52% | -26.59% | 29.69% | 133.07% |
Accounts Receivable | 71.27 | 58.97 | 24.74 | 61.59 | 44.75 |
Inventory | 17.33 | 13.57 | 12.87 | 12.63 | 9.52 |
Other Current Assets | 0.17 | - | - | - | 0.63 |
Total Current Assets | 185.65 | 133.19 | 141.33 | 215.5 | 163.84 |
Net Property, Plant & Equipment | 107.63 | 64.3 | 75.69 | 133.78 | 69.73 |
Other Intangible Assets | 25.17 | 29.22 | 30.98 | 105.89 | 0.05 |
Other Long-Term Assets | 7.28 | 4.93 | 4.34 | 5.01 | 3.61 |
Total Assets | 325.72 | 231.64 | 252.34 | 460.18 | 237.23 |
Accounts Payable | 35.36 | 26.17 | 17.8 | 36.58 | 19.06 |
Accrued Expenses | - | 1.15 | 0.75 | - | - |
Current Portion of Long-Term Debt | - | 0.28 | - | - | - |
Current Portion of Leases | 6.06 | 4.14 | 3.65 | 3.3 | 0.85 |
Unearned Revenue | 42.8 | 24.19 | 22.11 | 19.26 | 13.4 |
Other Current Liabilities | - | 2.39 | - | 0.53 | - |
Total Current Liabilities | 84.22 | 58.32 | 44.32 | 59.66 | 33.31 |
Long-Term Debt | 41.49 | 39.79 | 38.53 | 39.78 | - |
Long-Term Leases | 100.58 | 64.55 | 69.27 | 71.21 | 8.49 |
Other Long-Term Liabilities | 8.08 | 8.49 | 22.39 | 53.34 | 8.1 |
Total Long-Term Liabilities | 150.15 | 112.84 | 130.19 | 164.33 | 16.58 |
Total Liabilities | 234.37 | 171.16 | 174.51 | 223.99 | 49.89 |
Common Stock | 60.38 | 52.98 | 48.4 | 48.13 | 43.09 |
Additional Paid-in Capital | 445.85 | 394.86 | 380.33 | 379.95 | 307.77 |
Accumulated Other Comprehensive Income | 7.47 | 8.71 | -1.81 | -24.89 | 2.29 |
Retained Earnings | -422.35 | -399.5 | -352.92 | -198.55 | -165.81 |
Total Common Shareholders' Equity | 91.35 | 57.05 | 74.01 | 204.65 | 187.34 |
Minority Interest | - | 3.44 | 3.83 | 31.54 | - |
Shareholders' Equity | 91.35 | 60.49 | 77.83 | 236.19 | 187.34 |
Total Liabilities & Equity | 325.72 | 231.64 | 252.34 | 460.18 | 237.23 |
Total Debt | 148.13 | 108.76 | 111.46 | 114.28 | 9.34 |
Net Cash (Debt) | -51.24 | -48.11 | -7.74 | 27 | 99.6 |
Net Cash Growth | - | - | - | -72.89% | 202.76% |
Net Cash Per Share | -0.46 | -0.47 | -0.08 | 0.28 | 1.19 |
Book Value | 91.35 | 57.05 | 74.01 | 204.65 | 187.34 |
Book Value Per Share | 0.82 | 0.55 | 0.77 | 2.16 | 2.24 |
Tangible Book Value | 66.18 | 27.83 | 43.03 | 98.77 | 187.29 |
Tangible Book Value Per Share | 0.59 | 0.27 | 0.45 | 1.04 | 2.24 |